14th Annual Pacific Psychopharmacology Conference

14th Annual Pacific Psychopharmacology Conference

** VIRTUAL CONFERENCE **

Accreditation
Target Audience:

Psychiatrists, Primary Care Physicians, Pharmacists, Psychologists, Nurse Practitioners, Psychiatric Nurses, and Social Workers

Course Format: Full-day of plenary talks highlighted by interactive Q&A time.
  • Sep 25, 2020
Broadcast starts: 0800 PDT

Online from Vancouver
Full-Sized Map

Overview

Registration is now closed.


Join us for our most impressive line-up of speakers ever, all from the comfort of your office or home.

Our usual in-person conference will be going completely virtual this year and will feature international experts on depression, anxiety, schizophrenia, and evolving approaches to the psychiatric impacts of COVID-19. And as always, we will offer local expertise on other important topics in psychopharmacology. Participants will be able to interact with the speakers via a live Q&A board, with lots of time for audience questions. We look forward to seeing you online this fall!

 Join the conversation online: #PPPC2020 
 

Agenda

Click Here for AGENDA and LEARNING OBJECTIVES

Learning objectives will be added/updated as they are received.

0800 - 0805 Welcome and Opening Remarks Dr. Randall White

0805 - 0845
0845 - 0900

Antidepressants for Major Depression
Q&A Session 

During this presentation, participants will review:

  1. What is a network meta-analysis
  2. What is the best comparative evidence about antidepressants for major depression
  3. What is next in order to tailor treatment to individual patients 
Dr. Andrea Cipriani

0900 - 0940
0940 - 0955

The Role of Esketamine and Emerging Rapid Acting Antidepressants
Q&A Session

This presentation will:

  1. Review the unmet need in mood disorders
  2. Discuss the rationale for glutamate treatments in treatment-resistant depression
  3. Provide evidence for esketamine and ketamine in TRD
Dr. Roger McIntyre

0955 - 1025
1025 - 1040

Alcohol Use Disorder Guidelines
Q&A Session

At the end of this presentation, participants will be able to:

    1. Discuss the new standard of care and provincial guidelines for people with AUD
    2. Determine what issues may be keeping people from accessing evidence-based AUD care
    3. Develop greater compassion and hope for people with AUD and become a champion for this new standard of care
    Dr. Rupinder Brar

    1040 - 1100

    AM Break

     
    1100 - 1130
    1130 - 1145

    Anxiety, Depression and Neuropsychiatric Disorders in Older Adults
    Q&A Session

    This presentation will:

    1. Address the importance of natural history and age of symptom onset in assessing depression and anxiety in older adults
    2. Examine the etiological links between depression and neurocognitive disorders
    Dr. Zahinoor Ismail
    1145 - 1215
    1215 - 1230

    Evaluation and Treatment of Hospitalized Patients with CoVID-19
    Q&A Session

    At the end of this presentation, participants will be able to:

      1. Recognize the challenges arising from comorbidities of psychiatric disorders and COVID-19
      2. Learn to identify and treat behavioral complications of COVID-19 and behavioral complications associated with the treatment of COVID-19
      3. Recognize concepts of interventions that can minimize traumatic stress associated with hospitalization for COVID-19
      Dr. Damir Huremovic

      1230 - 1300

      Lunch Break

       
      1300 - 1345 CONCURRENT SESSIONS I  
       

      A)  Don’t Worry, You’ve Got This! Management of Pediatric Anxiety Disorders

      At the end of this presentation, participants will be able to:

      1. Choose the optimal pharmacotherapeutic approach to pediatric anxiety disorders from available treatment options.
      2. Contrast the benefits and risks of medications (e.g. SSRIs, SNRIs) when prescribed for pediatric anxiety disorders versus when prescribed for pediatric depressive disorders.
      Dr. Dean Elbe
       

      B)  Post CoVID-19 Psychiatric Outcomes  

      At the end of this presentation, participants will be able to:

      1. Identify the psychiatric complications associated with exposure to, and recovery from, COVID-19, including quarantine and isolation
      2. Recognize the effects of traumatic stress due to COVID-19 may have on families of patients, healthcare providers, and the broader community
      3. Describe the spectrum of interventions, including pharmacological interventions, aimed at treating COVID-19 psychiatric sequelae
      Dr. Damir Huremovic 
       

      C)  When Meth and Psychosis Come Together​

      At the end of this presentation, participants will be able to:

      1. Describe the relationship between methamphetamine use and psychotic symptoms/disorders.
      2. Review the current evidence on the efficacy of prescribed psychostimulant substitution.
      3. Discuss the complexities of safe supply of stimulants in patients with psychosis.
      Dr. Julius Elefante
      Mr. Reza Rafizadeh

      1345 - 1400

      PM Break

       
      1400 - 1445 CONCURRENT SESSIONS II  
       

      D)  Substance Use Disorders through an Occupational Lens

      At the end of this presentation, participants will have:

      1. Enhanced knowledge of the occupational impact of substances/medications
      2. Increased skills in applying a practical instrument to classify substances/medications as it relates to the impact on occupational capacity, risk, and tolerance
      3. Augmented confidence in applying workplace guidelines related to the consumption of cannabis
      Dr. Charl Els
       

      E)  Vaping and E-cigarettes

      During this presentation, participants will:

      1. Understand the growing practice of vaping amongst youth and it’s implications 
      2. Consider the potential harmful effects of vaping
      3. Review the evidence exploring a potential role of vaping products as a “harm reduction” or cessation tool
      4. Reflect on the current regulatory framework for vaping products and how this might be strengthened
      Dr. Milan Khara
       

      F)  Buprenorphine as a Monthly Long-Acting Injection: A new treatment option for opioid use disorder   

      At the end of this presentation, participants will:

      1. Describe the pharmacology, pharmacokinetics, dosing and administration, and adverse effects of buprenorphine monthly long-acting injection
      2. Summarize the evidence for efficacy and safety of buprenorphine monthly long-acting injection
      3. Recognize and respond to real-world challenges with use of buprenorphine monthly long-acting injection
      Dr. Nader Sharifi
      Dr. Tamara Mihic
      1445 - 1450 Quick Break  
      1450 - 1530
      1530 - 1545

      Antipsychotic Therapy
      Q&A Session

      At the end of this presentation, participants will:

      1. Be familiar with current guidelines for the identification of treatment resistance Schizophrenia
      2. Have an up to date perspective on the indications for clozapine treatment in Schizophrenia
      3. Have a better sense of the risks benefits associated with the clozapine treatment
      Dr. John Kane
      1545 Closing Remarks Dr. Jacky Siu

       

      Key Speakers

      Andrea Cipriani, MD, PhD

      Professor of Psychiatry, NIHR Research Professor; Director, Clinical Research Facility, Warneford Hospital, Oxford; Associate Director, R&D, Oxford Health NHS Foundation Trust, Oxford

      John Kane, MD

      Chairman of Psychiatry, Zucker Hillside Hospital, NY; Chairman, Psychiatry and Professor of Psychiatry & Molecular Medicine, Hofstra North Shore-LIJ School of Medicine

      Roger McIntyre, MD FRCPC

      Professor of Psychiatry and Pharmacology, University of Toronto; Head, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto; Executive Director, Brain and Cognition Discovery Foundation, Toronto

      Zahinoor Ismail, MD FRCPC

      Associate Professor, Community Health Sciences, Psychiatry, Hotchkiss Brain Institute, University of Calgary; Principal Investigator, Ron & Rene Ward Centre for Healthy Brain Aging Research

      Damir Huremovic, MD, MPP

      Director of Psychiatry, North Shore University Hospital, Manhasset, NY, Northwell Health, Inc.; Assistant Professor of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

       

       

      Cost

      Early bird registration: Mon. Aug 17, 2020 | Add to calendar +

        By AUG 17 After AUG 17
      Delegates $225 $250
      Residents & Students $50 $75

       

      All fees are in Canadian dollars. Fees are subject to 5% GST.

      Fees include: access to the live virtual event, all available materials, and access to the post-event recordings.

      Cancellations and Refunds

      You May Also Like

      Target Audience:

      BCPA Members, psychiatrists, residents & students

      Date: Nov 21, 2020
      Location:
      Conference starts 0900 AM
      Online from Vancouver  British Columbia
      Canada
      Target Audience:

      Family physicians, occupational physicians, specialty physicians, physiotherapists, psychiatrists, registered nurses, nurse practitioners, residents & students

      Date: Dec 5, 2020
      Location:
      Conference starts 0815 PST
      Online from Vancouver  British Columbia
      Canada
      Top
      More »